HER-2, notch, and breast cancer stem cells: Targeting an axis of evil

Hasan Korkaya, Max S. Wicha

Research output: Contribution to journalArticle

101 Scopus citations


Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse,suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.

Original languageEnglish (US)
Pages (from-to)1845-1847
Number of pages3
JournalClinical Cancer Research
Issue number6
StatePublished - Mar 15 2009
Externally publishedYes


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this